Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT phase II study for focal knee cartilage lesions
NL-OMON46367Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous chondrons + allogeneic mesenchymal stromal cells in chondral knee defect, cartilage defect of knee, sponsored by University Medical Center Utrecht. Planned start Jun 2018; status: withdrawn.
02
Drugs
autologous chondrons + allogeneic mesenchymal stromal cells
03
Conditions
chondral knee defectcartilage defect of knee
Beyond the preview
Go deeper on NL-OMON46367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46367.